• Cancer bioinformatics
• AI-powered precision oncology
• Innovative diagnostics and therapeutics development

Xin Wang’s primary research area is translational genomics and bioinformatics. He focuses on mechanistic and translational studies of major human cancers, developing novel methodologies that integrate bioinformatics, systems biology, machine learning, and artificial intelligence. In close collaboration with molecular biologists and experimental oncologists, he is particularly interested in dissecting cancer heterogeneity and elucidating the mechanisms underlying specific cancer subtypes. Working alongside clinicians, his team is dedicated to multi-center studies on molecular biomarkers and medical image-based AI models for early cancer detection, diagnosis, prognosis, and molecular subtyping. Moreover, leveraging new drug targets identified through integrative multi-omics analysis, his laboraotory develops innovative cancer therapeutics, including RIBOTACs, PROTACs, and mRNA vaccines.

Xin Wang is an Associate Professor in the Department of Surgery at The Chinese University of Hong Kong (CUHK) Faculty of Medicine. He also serves as the Director of the Division of Biomedical Informatics, Principal Investigator at the Li Ka Shing Institute of Health Sciences, and Coordinator of the Translational Genomics Program. He obtained his Ph.D. in Oncology from University of Cambridge, UK, in 2014, and subsequently conducted postdoctoral research in the Department of Biomedical Informatics at Harvard Medical School from 2013 to 2015.

Xin has published over 100 SCI papers in high-impact journals such as Nature Medicine, Gastroenterology, Gut, Hepatology, and Clinical Cancer Research. His notable scientific contributions include: establishing the consensus molecular subtypes (CMS) for colorectal cancer through large-scale multi-omics analysis, now a global standard (Nature Medicine 2013; 2015); elucidating subtype-specific regulatory mechanisms via multi-omics and systems biology (Nature Communications 2021; 2023); establishing the first consensus molecular subtypes for esophageal squamous cell carcinomas and developed AI-powered tool imECMS to advance and popularize precision medicine (Signal Transduction and Targeted Therapy 2026); developing non-invasive early detection biomarkers for esophageal, gastric, and ovarian cancers (Molecular Cancer 2022; JAMA Network Open 2021; Clinical Cancer Research 2021); and pioneering a liquid biopsy approach based on circulating exosomal small RNAs for pancreatic cancer (Gastroenterology 2022).

Committed to translating research into clinical practice, Xin holds 15 patents covering AI-assisted diagnosis using medical imaging and histopathology, miRNA liquid biopsies, mRNA-LNP vaccines, and RIBOTAC/PROTAC-based drug development. His team has received several prestigious awards, including the Second Prize of Natural Science Award from the Ministry of Education of China (2025), the Second Prize of Natural Science Award of the Wu Wenjun AI Science and Technology Award (2025), and two gold medals and one silver medal at the Geneva International Exhibition of Inventions (2026).

1. 2025 Wu Wenjun Artificial Intelligence Science and Technology Award (Natural Sciences), Chinese Association for Artificial Intelligence (2026)
2. Gold Medal for Project “Cell-selective delivery of an RNA degrader via an anti-EGFR nanobody for pancreatic cancer treatment”, 51st International Exhibition of Inventions Geneva (2026)
3. Gold Medal for Project “Methods for identifying non-canonical neoepitopes”, 51st International Exhibition of Inventions Geneva (2026)
4. Silver Medal for Project “CT4CMS: An intelligent system for non-invasive prediction of consensus molecular subtypes in colorectal cancer using preoperative CT images”, 51st International Exhibition of Inventions Geneva (2026)
5. Outstanding Scientific Research Achievement Award (Natural Sciences), National Ministry of Education, China (2025)
6. Best Poster Award, Gordon Research Conference Nasopharyngeal Carcinoma 2024, Switzerland (2024)

1. Chen D, Jiang X, Duan T, et al. NCOA4-mediated ferritinophagy: Emerging role and novel therapeutic target in precision oncology. Autophagy. 2026;():1-17. doi:10.1080/15548627.2026.2656779.
2. Cui H, Zhu Z, Xu E, Qi L, Cheng Y, Zhang Y, Zhang L, Cheng MY, Yang B, Sun R, Zhuang X, Xi Y, Yan T, Cheng C, Ding N, Liu H, Wang L, Guo M, Guo D, Zhang H, Peng M, An Z, Weng Y, Wang F, Liu M, Xiong R, Yin B, Song B, Zhang W, Cheng X, Liu Z, Zhan Q, Wang X, Cui Y. The consensus molecular subtypes of esophageal squamous cell carcinoma. Signal Transduct Target Ther. 2026;11(1):65. doi:10.1038/s41392-026-02577-9.
3. Ke J, Li Y, Qi L, Li X, Wang W, ten Hoorn S, Zhu Y, Huang H, Gao F, Vermeulen L, Wang X. Poor-prognosis young-onset colorectal cancer is defined by the mesenchymal subtype and can be predicted by integrating molecular and histopathological characteristics. ESMO Gastrointest Oncol. 2025;9:100181. doi:10.1016/j.esmogo.2025.100181.
4. Zhu, Y., Huang, C., Zhang, C., Zhou, Y., Zhao, E., Zhang, Y., Pan, X., Huang, H., Liao, W., & Wang, X. LncRNA MIR200CHG inhibits EMT in gastric cancer by stabilizing miR-200c from target-directed miRNA degradation. Nat Commun. 2023;14(1):8141. doi:10.1038/s41467-023-43974-w.
5. Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, Nishiwada S, Sharma G, Cridebring D, Zenhausern F, Kim S, Roe DJ, Darabi S, Han IW, Evans D, Yamada S, Demeure MJ, Becerra C, Merchant NB, Picozzi V, Borazanci EH, Von Hoff DD, GoelA. An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study. Gastroenterology. 2022;163(5):1252-1266.e2. doi:10.1053/j.gastro.2022.06.090.
6. Wu T, Huang H, Wang X. Dissecting super-enhancer heterogeneity: Time to re-examine cancer subtypes? Trends Genet. 2022;38(12):1199-1203. doi:10.1016/j.tig.2022.06.006
7. Miyoshi J, Zhu Z, Luo A, Toden S, Zhou X, Izumi D, Kanda M, Takayama T, Parker IM, Wang M, Gao F, Zaidi AH, Baba H, Kodera Y, Cui Y, Wang X, Liu Z, Goel A. A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: A retrospective, prospective and multicenter study. Mol Cancer. 2022;21(1):44. doi:10.1186/s12943-022-01507-x.
8. Wu J, Liu Q, Zhang X, Tan M, Li X, Liu P, Wu L, Jiao F, Lin Z, Wu X, Wang X, Zhao Y, Ren J. The interaction between STING and NCOA4 exacerbates lethal sepsis by orchestrating ferroptosis and inflammatory responses in macrophages. Cell Death Dis. 2022;13(7):653. doi:10.1038/s41419-022-05115-x.
9. Guo X, Peng Y, Song Q, Wei J, Wang X, Ru Y, Xu S, Cheng C, Li X, Wu D, Chen L, Wei B, Lv H, Ji G. A liquid biopsy signature for the early detection of gastric cancer in patients. Gastroenterology. 2023;165(2):402-413.e13. doi:10.1053/j.gastro.2023.02.044.
10. Kandimalla R, Wang W, Yu F, Zhou N, Gao F, Spillman M, Moukova L, Slaby O, Salhia B, Zhou S, Wang X, Goel A. OCaMIR—A noninvasive, diagnostic signature for early-stage ovarian cancer: A multi-cohort retrospective and prospective study. Clin Cancer Res. 2021;27(15):4277-4286. doi:10.1158/1078-0432.CCR-21-0267.
11. Huang H, Hu J, Maryam A, Huang Q, Zhang Y, Ramakrishnan S, Li J, Ma H, Ma VWS, Cheuk W, So GYK, Wang W, Cho WCS, Zhang L, Chan KM, Wang X, Chin YR. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling. Nat Commun. 2021;12(1):2290. doi:10.1038/s41467-021-22445-0.
12. Xie K, Wang Z, Qi L, Zhao X, Wang Y, Qu J, Xu P, Huang L, Yang Y, Wang X, Shi P. Profiling microRNAs with associated spatial dynamics in acute tissue slices. ACS Nano. 2021;15(3):4881-4892. doi:10.1021/acsnano.0c09676.
13. Shao X, Tan M, Xie Y, Yao C, Wang T, Huang H, Zhang Y, Ding J, Liu J, Han L, Hua C, Wang X, Deng X. Integrated regulatory network in Pseudomonas syringae reveals dynamics of virulence. Cell Rep. 2021;34(13):108920. doi:10.1016/j.celrep.2021.108920.
14. Wan YC, Liu J, Zhu L, Kang TZE, Zhu X, Lis J, Ishibashi T, Danko CG, Wang X, Chan KM. The H2BG53D oncohistone directly upregulates ANXA3 transcription and enhances cell migration in pancreatic ductal adenocarcinoma. Signal Transduct Target Ther. 2020;5(1):109. doi:10.1038/s41392-020-00219-2.
15. Wang Z, Qi L, Yang Yang, Lu M, Xie K, Zhao X, Cheung EHC, Wang Y, Jiang X, Zhang W, Huang L, Wang X, Shi P. High-throughput intracellular biopsy of microRNAs for dissecting the temporal dynamics of cellular heterogeneity. Sci Adv. 2020;6(24):eaba4971. doi:10.1126/sciadv.aba4971.
16. Gao F, Wang W, Tan M, Zhu L, Zhang Y, Fessler E, Vermeulen L, Wang X. DeepCC: A novel deep learning-based framework for cancer molecular subtype classification. Oncogenesis. 2019;8(1):44. doi:10.1038/s41389-019-0157-8.
17. Chen H, Gao F, He M, Ding XF, Wong AM, Sze SC, Yu AC, Sun T, Chan AWH, Wang X, Wong N. Long-read RNA sequencing identifies alternative splice variants in hepatocellular carcinoma and tumor-specific isoforms. Hepatology. 2019;70(3):1011-1025. doi:10.1002/hep.30500.
18. Kandimalla R, Gao F, Li Y, Huang H, Ke J, Deng X, Zhao L, Zhou S, Goel A, Wang X. RNAMethyPro: A biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. npj Precis Oncol. 2019;3:13. doi:10.1038/s41698-019-0085-2.
19. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. doi:10.1038/nm.3967
20. De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, Rodermond H, van der Heijden M, van Noesel CJ, Tuynman JB, Dekker E, Markowetz F, Medema JP, Vermeulen L. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614-618. doi:10.1038/nm.3174.